GlobeNewswireAPR 272 min read$HRTX

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

Heron Therapeutics announced it will report its first quarter 2026 financial results on Monday, May 11, 2026, through a conference call and live webcast. The event, scheduled for 8:30 a.m. ET, will also cover recent business highlights. Interested parties can access dial-in details via a registration link or the Investor Relations section of the company's website.

Original reporting

GlobeNewswire

Published Apr 27, 2026, 9:30 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Apr 27, 2026, 10:00 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 — source image — Source · GlobeNewswire

Decision brief

The 30-second read

$HRTXNeutralMed

Why it matters

Earnings results will provide insights into the company's financial health and growth prospects, influencing stock performance.

Market read

The upcoming earnings report is a significant event for HRTX investors and could influence sector sentiment.

What to watch

Market-wide macroeconomic conditions and sector-specific news could overshadow earnings impact.

Timing: High, as the event is scheduled for May 11, 2026.

Background

Heron Therapeutics specializes in developing and commercializing therapies for pain management and other indications.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HRTXNeutralMedium confidence

Context

Heron Therapeutics upcoming earnings report scheduled for May 11, 2026, is the primary focus.

Expected impact

Potential short-term increase or decrease of 5-10% around the earnings date, contingent on results.

Evidence & confidence

Earnings reports often cause volatility; however, without prior earnings data or consensus estimates, the impact remains uncertain.

Market effects

Sector

Potential influence on the biotech and life sciences sectors depending on Heron Therapeutics' results.

Regional

Limited, primarily affecting US markets where the company is based.

Global

Minimal, unless results significantly deviate from expectations, prompting broader biotech sector movements.

Counterpoint

What could challenge this read

Disappointing earnings could lead to a significant decline, suggesting caution in bullish positions.

Key entities

Company
Heron Therapeutics
A biotech firm focused on pain management therapies.

Read at source ← All news

AUG 29

$FULCMed

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?

Fulcrum Therapeutics (FULC) fell 51% to a 52-week low of $2.9 after halting development of its lead sickle cell disease treatment due to FDA cancer risk concerns. Heron Therapeutics (HRTX) dropped 45% to $0.44 following a court ruling invalidating key patents for CINVANTI. MicroVision (MVIS) declined 32% to $0.4 after proposing a reverse stock split to meet Nasdaq requirements.

stocktwits.com2 min

AUG 17

$HRTXMedAI 8/10

Heron (HRTX) Q2 2026 Earnings Call Transcript

Heron Therapeutics (HRTX) reported Q2 2026 net revenue of $37.7M, up from $34.7M in Q1 but below expectations. CINVANTI was $21.8M, ZYNRELEF $11.1M (+35% YoY), and APONVIE $4.2M (+74% YoY). After a June patent ruling, the company amended its Hercules credit facility, resetting covenants through 2027 and reducing principal. It withdrew full-year 2026 guidance.

yahoo.com7 min

AUG 10

$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

yahoo.com6 min

AUG 10

$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-year - Amended credit facility with Hercules

SEC EDGAR 8-K6 min

SEP 8

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min